Iksuda Therapeutics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Helix Draymans Newcastle Way, Newcastle ...Phone Number
+44 1916031680Website
www.iksuda.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Iksuda Therapeutics
Founded in 2007, headquartered in Newcastle upon Tyne, UK, About Iksuda Therapeutics is a biotechnology company focussed on the development of next generation Antibody Drug Conjugates (ADCs) designed to combat difficult-to-treat tumours, including those that are resistant or refractory to current treatment regimens. Iksuda's pipeline of stable and superior ADCs is centered on its highly stable PermaLink® conjugation platform in combination with a portfolio of highly potent cytotoxic payloads designed to enhance antitumor activity and improve the lives of cancer patients.Explore more
Iksuda Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iksuda Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Iksuda Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Iksuda Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Iksuda Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Iksuda Therapeutics
Product Launch: Get notified when Iksuda Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Iksuda Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Iksuda Therapeutics has new funding data
Iksuda Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Iksuda Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Iksuda Therapeutics
Compare insights from companies similar to Iksuda Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.5M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
Company Profile Activity
Activity Insights
Iksuda Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Iksuda Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Iksuda Therapeutics.
Iksuda Therapeutics financials insights
Gather financial insights about Iksuda Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$47M
Iksuda Therapeutics Tech Stack
A closer look at the technologies used by Iksuda Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Funding
Iksuda Therapeutics News & Media
Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of dosing of its first patient with IKS03, a CD19-directed ADC, in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma. This first-in-human study (https://clinicaltrials.gov/study/NCT05365659) will evaluate the safety, tolerabIksuda to Present Growing ADC Pipeline at AACR
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois (25-30 April). The posters cover the Company’s new payload class, the ProAlk series, its CA242-directed ADC, IKS04, being developed for the treatment of gastrointestinal (GI) cancers, and its proprietary PIksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading antibody drug conjugates (ADCs) with enhanced tumour specificity, today announces that the first patient has completed a first cycle of therapy with IKS014, a human epidermal growth factor receptor 2 (HER2) ADC targeting patients with advanced HER2+ solid tumours. This follows positive data from Phase 1 clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through Phase 2New year, new ADC deal: Abzena teams up with BiVictriX, Iksuda taps LegoChem again ...
The past few weeks have witnessed a plethora of antibody-drug conjugate (ADC) related deals.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Iksuda Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2007, headquartered in Newcastle upon Tyne, UK, About Iksuda Therapeutics is a biotechnology company focussed on the development of next generation Antibody Drug Conjugates (ADCs) designed to combat difficult-to-treat tumours, including those that are resistant or refractory to current treatment regimens. Iksuda's pipeline of stable and... Read More
